Merger29 May 2025, 10:12 am
Sequent Scientific's Merger with Viyash Life Sciences Progresses, NCLT Filing Underway
AI Summary
Sequent Scientific, a leading player in the global animal health industry, has secured approvals from the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) for its proposed merger with Hyderabad-based Viyash Life Sciences. The company has now filed for clearance with the National Company Law Tribunal (NCLT), marking a crucial milestone in the merger process. The merger will bring together two strong business verticals—Global Animal Health and a world class API business, unlocking access to over 150 countries. The combined entity will benefit from a five-fold increase in R&D talent and a nine-fold expansion in USFDA-approved manufacturing capacity, creating a robust and scalable operating backbone.
Key Highlights
- Sequent Scientific secures approvals from NSE and BSE for its proposed merger with Viyash Life Sciences
- Company files for clearance with the National Company Law Tribunal (NCLT)
- Merger will bring together Global Animal Health and a world class API business
- Combined entity will benefit from a five-fold increase in R&D talent and a nine-fold expansion in USFDA-approved manufacturing capacity
- Carlyle, a US-based private equity firm, holds a 53% stake in SeQuent and is the majority shareholder in privately held Viyash